We have used two-dimensional electrophoresis of enzyme-digested genomic DNA to identify a novel gene GAC1, which maps at 1q32.1 and which is overexpressed in malignant gliomas in which it is ampli®ed. GAC1 encodes a protein which belongs to the leucine-rich repeat superfamily. Ampli®cation and overexpression of GAC1 was demonstrated in two of eight tumors where ampli®cations were previously evidenced by comparative genomic hybridization (one glioblastoma multiforme and one anaplastic astrocytoma), and in one of eight unselected glioblastomas multiforme. GAC1 exhibits sequence homology with other proteins which function as cell-adhesion molecules or as signal transduction receptor and is a likely candidate for the target gene in the 1q32.1 amplicon in malignant gliomas.
Introduction
Malignant gliomas are the most common primary tumors of the adult central nervous system. The most malignant form, the glioblastoma multiforme (GBM) may develop secondarily from lower-grade gliomas (astrocytomas, oligodendrogliomas or oligoastrocytomas) or may occur de novo (Louis and Gusella, 1995) . The molecular and pathogenic mechanisms leading to the malignant transformation are poorly understood. Among the various chromosome aberrations detected in gliomas (Collins, 1995) , the most frequent ®ndings have been trisomy 7, monosomy 10 and 22 and deletions of 9p and 17p arms. Chromosome rearrangements involving in particular chromosomes 1 and 9 and double minute chromosomes (dmin) have occurred recurrently. Dmin, which contain ampli®ed genes, are found in 50% of glioblastomas. Ampli®ed genes are less commonly detected in the astrocytomas. Epidermal growth factor receptor gene (EGFR) ampli®cation is the most common type of alteration found in glioblastomas: about 40% of these tumors amplify and overexpress EGFR. Only a few additional genes have been shown to be ampli®ed and overexpressed recurrently: in the 12q13-14 amplicon, CDK4, SAS and MDM2 are ampli®ed in 15%, 15% and 10% of the cases respectively, whereas the platelet-derived growth factor receptor A (PDGFRA) is ampli®ed in 5 ± 8% of the glioblastomas. Other genes, including GLI, MYC, NMYC, MET are ampli®ed at lower frequency.
Until recently, the detection of ampli®ed genes in a tumor type has been based on the screening of candidate genes, most of which having been previously found to be ampli®ed in other tumors. The introduction of comparative genomic hybridization (CGH) has allowed identi®cation of ampli®ed regions in the genome of tumor cells without the need to probe for any particular gene(s). Such systematic studies have shown that in human solid tumors, numerous regions of ampli®cation encompassed as yet unknown ampli®ed genes (Forozan et al., 1997) . In a prior study of genomic aberrations in gliomas by CGH, we have observed ampli®cation involving precisely chromosome band 1q32.1 in two of nine tumors selected for the presence of dmin . In another study, one GBM exhibited 1q32 ampli®cation among nine gliomas investigated (SchroÈ ck et al., 1994) . The CGH approach gives no direct information as to the target gene(s) of the ampli®cation and therefore other means are needed to uncover genes encompassed in ampli®ed chromosome regions detected by CGH.
Two-dimensional electrophoresis of enzyme-digested genomic DNA provides the means to search for genomic changes in tumors (Asakawa et al., 1994; Kuick et al., 1995; Wimmer et al., 1997; Costello et al., 1997) . By utilizing dierent combinations of restriction enzymes and/or dierent electrophoretic conditions, the number of independent fragments in a human genomic DNA sample that can be analysed in multiple 2-D patterns can reach several thousand. The visualization of 2-D patterns relies on radioisotope labeling of genomic fragments at cleavage sites speci®c for a rare cutting restriction enzyme. The labeled genomic digests are separated in a ®rst dimension, followed by in situ digestion prior to second-dimension separation. The reliance on the rare cleaving restriction enzyme NotI to digest genomic DNA prior to labeling, allows visualization of DNA fragments that occur preferentially in CpG islands of the genome (Lindsay and Bird, 1987) . Because of the localization of CpG islands in proximity to transcribed sequences (Larsen et al., 1992) , the 2-D patterns obtained with this enzyme are highly targeted to a functional component of the genome. Thus, there is a strong likelihood that NotI fragments detected in 2-D gels represent sequences in genes.
We have utilized the 2-D DNA approach to identify genes encompassed in the 1q32.1 region ampli®ed in gliomas . We report the identi®cation of a novel gene which maps at 1q32.1 and which is ampli®ed in tumors with 1q32.1 ampli®cation. The gene encodes a protein which belongs to the leucine-rich repeat superfamily and is overexpressed in tumors in which it is ampli®ed.
Results
An ampli®ed genomic fragment in gliomas with 1q32.1 ampli®cation Genomic 2-D DNA patterns were obtained for a GBM tumor (No 26) which was previously found to exhibit 1q32.1 ampli®cation by CGH . Patterns were prepared using the enzyme combinations NotI ± EcoRV for the ®rst dimension and either HinfI or DpnII for the second dimension. The patterns obtained were compared to a large database of patterns prepared from a variety of normal tissues including brain, lung, gastrointestinal tissues and blood cell populations. A multicopy fragment was observed in the NotI ± EcoRV ± DpnII pattern of the glioma tumor which occurred at an intensity corresponding to approximately 50 copies in the genome. This fragment occurred at an intensity corresponding to two copies in the genome of normal tissues analysed ( Figure 1 ). The size of the ampli®ed fragment was 1.9 kb after the ®rst-dimension digestion with NotI ± EcoRV and 1.4 kb after the second dimension digestion with DpnII. A partially overlapping 2-D pattern for this tumor, obtained with HinfI as the second-dimension cutter did not reveal any ampli®ed fragment with a 1.9 kb size in the ®rst dimension. This suggests that the NotI ± HinfI fragment in the ampli®ed region detected in the NotI ± EcoRV ± DpnII pattern was smaller than the size limit of 150 bp in the second dimension separation. Most other multicopy-fragments observed in either NotI ± EcoRV ± DpnII or NotI ± EcoRV ± HinfI patterns of the tumor corresponded to fragments derived from ribosomal DNA genes (Kuick et al., 1996) . Eight other glioblastomas that were not cytogenetically characterized were also analysed by the same technique. The ampli®ed fragment of tumor 26 was found to be ampli®ed in an additional tumor (No 295) (Figure 1 ).
The ampli®ed NotI ± DpnII fragment contains transcribed sequences
The ampli®ed NotI ± DpnII fragment from tumor 26 was cloned as described in Materials and methods. A clone with a 1.4 kb insert corresponding to the size of the NotI ± DpnII fragment was isolated. FISH analysis using the cloned fragment as a probe showed hybridization at 1q32.1 (not shown), corresponding to the location of the ampli®ed region detected by CGH . Partial sequencing of the clone revealed a 32 bp sequence which matched EST 06184 (clone HIBBB95). The corresponding cDNA clone was derived from a library made from normal brain RNA (Adams et al., 1993) . FISH analysis using clone HIBBB95 showed hybridization at 1q32.1 (Figure 2 ). Sequence analysis of the cloned NotI ± DpnII fragment revealed the presence of a HinfI site at 101 bp from the NotI site, which accounts for the absence of the ampli®ed fragment in NotI ± EcoRV ± HinfI patterns, as the short NotI ± HinfI fragment would have migrated o the gel. The clone HIBBB95 was sequenced and the sequence extended in the 3' direction by RACE. A continuous 3227 base pair cDNA sequence (GAC1, for glioblastoma ampli®cation on chromosome 1) could be deduced from the sequence of overlapping clones (Genbank accession number AF030435
). An open reading frame begins at nucleotide 389, within an appropriate Kozak's consensus sequence for the initiation of translation (Kozak, 1984) , and terminates at nucleotide 2530, encoding a putative protein of 713 amino acids, with a calculated molecular mass of 79 kDa. Three AATAA polyadenylation signals were found at the 3' end, followed by a poly A stretch. Southern blot analysis (Figure 3 ) demonstrated hybridization to a 10 kb EcoRI fragment ampli®ed in the original tumor 26 as well as in the second tumor (No 25) which also presented a CGH ampli®cation signal at 1q32.1 in a previous study . The copies number was estimated at 40 ± 50 for tumor 26 and 20 ± 25 for tumor 25. Thus both tumors for which CGH suggested 1q32.1 ampli®cation also exhibited ampli®cation of GAC1. The expression of GAC1 in tumors was determined by Northern blot analysis (Figure 4) . A band corresponding to a mRNA of about 3.5 kb was detected in normal brain and in 16 glial tumors; it was overexpressed in tumor 25, 26 and 295, all three of which contained the ampli®ed gene as shown by two dimensional gel electrophoresis and/or by Southern blot analysis (Figures 1 and 3) . Tumors 26 and 295 were primary glioblastomas multiforme. Tumor 25 was a primary anaplastic astrocytoma. Analysis of GAC1 expression in human adult tissues revealed that the 3.5 kb transcript was present, in heart and kidney but at a lower level than in brain and was not detectable in placenta, lung, liver, skeletal muscle and pancreas ( Figure 5 ).
Characterization of the GAC1 protein
Hydrophobicity pro®le analysis revealed that GAC1 has properties of a transmembrane protein (Figure 6 ). Two hydrophobic segments were observed at the amino terminus (amino acid 1 ± 28) and at the carboxy terminus (amino acid 629 ± 650) for sequences representing a putative signal peptide (von Heijne, 1986 ) and a transmembrane region, respectively. GAC1 protein belongs to the leucine-rich repeat (LRR) superfamily (Buchanan and Gay, 1996) as evidenced by the presence at positions 71 ± 369, of a tandem array of 12 full length LRR motifs of 24 ± 25 residues, of which the consensus can be described as LX 2 LXLX 2 NXLX 2 aX 4 FX 2 LX 2 (in which`a' denotes an aliphatic residue and`X' any amino acid). The LRR block is¯anked by a typical cysteine-rich carboxylanking region of sequence PX 2 CXCX 23 CX 22 C. In contrast, the cysteine-rich amino¯anking sequence is GAC1 exhibited homology with three transmembrane proteins mainly expressed in the mouse nervous system: NLRR-1, NLRR-2 and NLRR-3 (Taguchi et al., 1996; Taniguchi et al., 1996) . The full coding sequences are available for NLRR-1 (716 amino acid) and NLRR-3 (707 amino acid), however only some of the LRR were sequenced for NLRR-2. Excluding the signal, the transmembrane and the intracellular regions for which no signi®cant homologies were found, the identity with GAC1 was 72% for NLRR-1 and 56% for NLRR-3. Only one of the 79 known amino acids of NLRR-2 was dierent from the corresponding sequence of GAC1.
Lower levels of homologies, restricted to the LRR block were found with the drosophila proteins slit and tartan both presumably functioning in adhesion events. Tartan is a transmembrane protein with a primary structure close to GAC1 protein whereas slit is a secreted protein devoid of transmembrane peptide (Buchanan and Gay, 1996) . Signi®cant homologies were also found in the LRR block with the acid-labile subunit (ALS) of the insulin-like growth factor-binding protein circulating complex (Leong et al., 1992) .
Renin gene co-ampli®cation
The renin gene (REN), localized in band 1q32 (Qin et al., 1993) , has been found to be ampli®ed in one case in a study of 37 glial tumors by Southern blot analysis (Reifenberger et al., 1994) . In the present study, REN was found ampli®ed in tumors 25 and 26 (DNA from tumor 295 was not available for Southern analysis) (Figure 3) . Overexpression of REN was not found in the tumors in this series (not shown).
Two genes encoding LRR-containing small proteoglycans, ®bromodulin (Sztrolovics et al., 1994) and PRELP (Grover et al., 1996) , both localized in the extracellular matrix, have been previously mapped in band 1q32. Southern analysis showed that neither of these two genes is ampli®ed with GAC1 in the tumors with an ampli®cation at 1q32.1 (not shown).
Discussion
We used two dimensional electrophoresis of genomic DNA from a GBM to identify a gene which we designated GAC1 and which is ampli®ed in some gliomas. This gene is localized in band 1q32.1, a region previously found to be ampli®ed in this tumor by CGH. The protein encoded by GAC1 is a transmembrane protein belonging to the LRR-containing superfamily. The ampli®cation and expression status of GAC1 was studied in a series of 16 gliomas. Eight were previously analysed by CGH, two of which showed evidence of 1q32.1 ampli®cation. These two tumors showed ampli®cation of GAC1. Eight other GBM tumors were investigated by 2-D genomic analysis without previous CGH study or prior knowledge of any ampli®cation. One of the additional GBM tumors showed ampli®cation of GAC1. In the three cases of ampli®cation found in the present study, the GAC1 gene was overexpressed and there was no overexpression in other tumors without ampli®cation of the gene. REN was coampli®ed with GAC1 but was not overexpressed in tumors with ampli®cation. The two genes appear to be closely linked. However, GAC1 seems to be a more likely target gene of the amplicon.
The LRR-containing protein superfamily comprises an increasing number of intracellular and extracellular proteins with diverse functions (Buchanan and Gay, 1996; Kobe and Deisenhofer, 1994; Iozzo, 1997) . All proteins containing these repeats are thought to be involved in protein-protein interactions. Adhesive proteins represent the largest group in the superfamily and include the small proteoglycans which bind various components of the extracellular matrix and growth factors. The LRR superfamily contains also several families of signal-transducing receptors.
Some members of the superfamily are associated with and function in the nervous system of Drosophila. For example connectin functions in neuromuscular junction formation (Nose et al., 1992) , slit plays a role in axon development (Rothberg et al., 1990) , chaoptin is involved in photoreceptor-cell development (Krantz and Zipursky, 1990 ) and tartan plays a role in neural and muscle development (Chang et al., 1993) . In the vertebrate nervous system, several molecules have been studied. In the human, they include the receptor kinase trk family, whose alterations in the extracellular domain can cause oncogenic activation (Meakin and Shooter, 1992) ; the oligodendrocyte-myelin glycoprotein which may be involved in cell-cell interactions (Mikol et al., 1990) and p37MB which was cloned from neuroblastoma cells, the function of which is unknown (Kim et al., 1996) . In the mouse, four proteins NLRR- Figure 6 Primary structural properties of the GAC1 protein (713 amino acids). Potential signal peptide (1 ± 28, double underlined); amino-¯anking truncated sequence (29 ± 35); LRRs (71 ± 369), each of the 12 repeats given as a successive line, a truncated thirteenth repeat is present; carboxy-¯anking sequence (370 ± 420); transmembrane domain (629-650, double underlined); cytoplasmic region (651-713). Four potential N-linked glycosylation sites corresponding to the sequence NXT are underlined 1, NLRR-2 and NLRR-3 and LIG-1 of unknown function have been described (Taguchi et al., 1996; Taniguchi et al., 1996; Suzuki et al., 1996) .
The GAC1 protein appears to be related to the NLRR proteins. Its primary amino acid structure does not allow a de®nitive conclusion about its biological function. However given its transmembrane nature and since all the LRR proteins with cysteine-rich carboxyl and amino¯anking regions appear to be involved in cell adhesion or function as receptors (Kobe and Deisenhofer, 1994) , the GAC1 protein is likely to function as a cell adhesion molecule or signal transducing receptor. As GAC1 protein has no signaling domain in the cytoplasm and shares weak similarity with ALS, the protein could function as a stabilizer for ligand binding. Its expression in other tissues than brain suggests that its role may not be limited to the nervous system.
Materials and methods

Tumor samples
Six xenografted GBM tumors (Nos 7, 11, 21, 23, 24 and 26) , one fresh stage III oligodendroglioma tumor (No 22) and one fresh anaplastic astrocytoma II tumor (case 25) bearing ampli®cation were previously described . Eight additional previously uncharacterized GBM tumors were also analysed (Nos 205, 223, 225, 261, 269, 293, 295, 313) . The fresh tumors were snap frozen in liquid nitrogen immediately after surgical excision. All tumors were obtained following informed consent and Institutional Review Board approval. DNA and RNA were prepared according to standard procedures.
Preparation of 2-D gels of genomic DNA
For the studies described, whole genomic DNA is digested with NotI and EcoRV, two six base-pair cutting enzymes (Kuick et al., 1995) . The protruding ends produced by the methylation sensitive CpG speci®c enzyme NotI are isotopically labeled. About 1 mg of the resulting DNA fragments is subjected to disc-agarose-gel electrophoresis to separate fragments in the 1.0 ± 5.0 and 5.0 ± 12.0 kb range. The separated DNA fragments are subsequently subjected to further in situ cleavage with a third frequently cutting restriction enzyme (HinfI or DpnII) and electrophoresed in a second dimension in polyacrylamide gels. The resulting 0.3 to 2.0 kb fragments are visualized using phosphor storage technology. The level of ampli®cation was estimated by quanti®cation of the radioactive spots. Not ampli®ed spots were used as standard. The digitized images are analysed using software we have previously developed (Kuick et al., 1995) .
